Bronchiectasis – Pipeline Review, 2019

According to the American Lung Association, bronchiectasis is characterized as a chronic disease condition in which the bronchi of the lungs expand and thicken leading to infection and inflammation. People suffering from bronchiectasis experience persistent cough and breathlessness. Bronchiectasis can be caused due to allergies or previous lung infection. According to the American Thoracic Society, there is no definitive known prevalence of bronchiectasis however, it is estimated that about 25 people in 100,000 suffer from the medical condition and the geriatric population is more predisposed to the disease.

The first line of treatment of bronchiectasis involves antibiotics to work against the bacterial infection. The antibiotics are prescribed on the basis of the severity and progression of the medical condition. Antibiotics like macrolides and nebulizers are often used to ease the inflammation cause by the infection.

Pharmaceutical companies in collaboration with various research and government organizations institutes have been focusing on developing and studying novel therapeutic options for the treatment of bronchiectasis. For instance; VX-371 which is being studied by Vertex Pharmaceuticals Incorporated in collaboration with Parion Sciences, is currently in phase-2 clinical trials for the study of efficacy of the drug in children suffering from primary ciliary dyskinesia that could lead to bronchiectasis.

As of 2019, around 43% of the pipeline candidates for bronchiectasis are in the phase-3 clinical trials. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Bronchiectasis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bronchiectasis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bronchiectasis.

The report on ‘Bronchiectasis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Bronchiectasis


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Bronchiectasis


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary